(Q36303951)

13 August 2017

1 reference

title

Technology insight: Applications of emerging immunotherapeutic strategies for Epstein-Barr virus-associated malignancies (English)

1 reference

13 August 2017

0 references

1 reference

Rajiv Khanna

1

1 reference

13 August 2017

Denis Moss

series ordinal

2

1 reference

13 August 2017

Maher Gandhi

series ordinal

3

1 reference

13 August 2017

publication date

1 March 2005

1 reference

Nature Clinical Practice Oncology

13 August 2017

published in

1 reference

13 August 2017

volume

2

1 reference

13 August 2017

issue

3

1 reference

13 August 2017

page(s)

138-149

1 reference

Epstein-Barr virus: 40 years on

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Selection pressure-driven evolution of the Epstein-Barr virus-encoded oncogene LMP1 in virus isolates from Southeast Asia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Epstein-Barr virus-associated Hodgkin's lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma: positive effect on overall and progression-free survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Chemokines, cytokines and their receptors in Hodgkin's lymphoma cell lines and tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Adoptive immunotherapy with allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T-lymphocytes for recurrent, EBV-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Adoptive transfer of allogeneic Epstein-Barr virus (EBV)-specific cytotoxic T cells with in vitro antitumor activity boosts LMP2-specific immune response in a patient with EBV-related nasopharyngeal carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

B cells under influence: transformation of B cells by Epstein–Barr virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

One step ahead of the game: viral immunomodulatory molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

A critical role for Stat3 signaling in immune tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Epstein-Barr virus-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kappaB pathway involving TNF receptor-associated factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Epstein-Barr virus (EBV) LMP2A mediates B-lymphocyte survival through constitutive activation of the Ras/PI3K/Akt pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Tolerance and cancer: mechanisms of tumor evasion and strategies for breaking tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Azacitidine induces demethylation of the Epstein-Barr virus genome in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Proteasomal targeting of a viral oncogene abrogates oncogenic phenotype and enhances immunogenicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Targeting of EBNA1 for rapid intracellular degradation overrides the inhibitory effects of the Gly-Ala repeat domain and restores CD8+ T cell recognition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Dual stimulation of Epstein-Barr Virus (EBV)-specific CD4+- and CD8+-T-cell responses by a chimeric antigen construct: potential therapeutic vaccine for EBV-positive nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Anti-cytokine Ab immune therapy: present status and perspectives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Anti-CD45-mediated cytoreduction to facilitate allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

Genome-wide scan for familial nasopharyngeal carcinoma reveals evidence of linkage to chromosome 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Salted fish and nasopharyngeal carcinoma in southern Chinese

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

The extracellular domain of the Epstein-Barr virus BZLF2 protein binds the HLA-DR beta chain and inhibits antigen presentation

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

The LMP2A signalosome--a therapeutic target for Epstein-Barr virus latency and associated disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Harnessing the ubiquitination machinery to target the degradation of specific cellular proteins

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Establishment and characterization of a bank of cytotoxic T lymphocytes for immunotherapy of epstein-barr virus-associated diseases

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Induction of therapeutic T-cell responses to subdominant tumor-associated viral oncogene after immunization with replication-incompetent polyepitope adenovirus vaccine

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Making room for T cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPONC0107

7 January 2021

Identifiers

DOI

10.1038/NCPONC0107

1 reference

Dimensions Publication ID

13 August 2017

1018646620

0 references

1 reference